Premium
Validity of the EQ ‐5D in patients with pemphigus vulgaris and pemphigus foliaceus
Author(s) -
Tamási B.,
Brodszky V.,
Péntek M.,
Gulácsi L.,
Hajdu K.,
Sárdy M.,
Szegedi A.,
BataCsörgő Z.,
Kinyó Á.,
Rencz F.
Publication year - 2019
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.16883
Subject(s) - pemphigus foliaceus , pemphigus vulgaris , medicine , dermatology life quality index , visual analogue scale , pemphigus , eq 5d , quality of life (healthcare) , depression (economics) , anxiety , population , severity of illness , dermatology , physical therapy , health related quality of life , disease , immunology , autoantibody , psychiatry , nursing , macroeconomics , environmental health , economics , antibody
Summary Background No studies to date have employed the EuroQoL EQ ‐5D questionnaire to assess health‐related quality of life ( HRQ oL) in patients with pemphigus. Objectives To evaluate the HRQ oL of patients with pemphigus by the EQ ‐5D and to analyse the convergent and known‐groups validity of the EQ ‐5D in this patient population. Methods Between 2014 and 2017, a multicentre cross‐sectional study was carried out. Outcome measures included the five‐level EQ ‐5D ( EQ ‐5D‐5L), Dermatology Life Quality Index ( DLQI ), Autoimmune Bullous Skin Disorder Intensity Score ( ABSIS ) and an average pain intensity visual analogue scale ( VAS ) for the past 3 months. Results In total, 109 consecutive patients with pemphigus participated in the study (mean age 57 years; 64% women). Among the EQ ‐5D dimensions, the most problems were reported regarding pain/discomfort (50%), mobility (43%) and anxiety/depression (43%). No significant difference was found in mean EQ ‐5D index scores between patients with pemphigus vulgaris and those with pemphigus foliaceus (0·81 vs. 0·86, P = 0·14). The mean EQ ‐5D index scores of patients with limited, moderate, significant and extreme pemphigus were 0·88, 0·82, 0·72 and 0·67, respectively ( P = 0·001). The number of comorbidities was associated with greater impairment in EQ ‐5D index scores ( P < 0·001). DLQI ( r s = −0·62, P < 0·001) and the average pain intensity VAS ( r s = −0·59, P < 0·001) more strongly correlated with the EQ ‐5D index scores than did ABSIS ( r s = −0·40, P < 0·001). Conclusions This is the first study employing the EQ ‐5D questionnaire in pemphigus. The EQ ‐5D is a valid measure of HRQ oL in patients with pemphigus that can be useful both in clinical practice and in economic evaluations to assess the health gains associated with new effective treatments.